COVID Card Pilot Study to Detect Antibodies to SARS-CoV-2

CompletedOBSERVATIONAL
Enrollment

56

Participants

Timeline

Start Date

August 31, 2022

Primary Completion Date

April 21, 2023

Study Completion Date

April 21, 2023

Conditions
COVID-19SARS-CoV2 Infection
Interventions
DEVICE

Novel point-of-care, semi-quantitative test for SARS-CoV-2 antibodies

"A drop of blood obtained by both finger-prick and venipuncture will be placed on the test card, which has been activated by the addition of diluent. Visual clumping of red blood cells (RBCs) will be seen within minutes if SARS-CoV-2 antibodies are present. Additionally, the COVID card is semi-quantitative, meaning that the yielded hemagglutination pattern will correlate with the concentration of antibodies in the serum.~A research team member will be present at bedside to provide their interpretation based on an established visual agglutination scoring system."

Trial Locations (1)

21201

University of Maryland Medical Systems, Baltimore

All Listed Sponsors
lead

University of Maryland, Baltimore

OTHER